Vogenx, Inc. (Nasdaq:VOGX) has appointed Ken Toombs to its Board of Directors, with the change taking effect on September 21, 2026. Toombs will serve as an independent director and Chair of the Audit Committee as the Raleigh, North Carolina-based clinical-stage biopharmaceutical company continues operations after its August 2026 initial public offering.
#Ken Toombs’ professional background
Toombs brings thirty years of experience in the global professional services sector. His most recent role was Chief Executive Officer of PA Consulting, the London-headquartered innovation and transformation consultancy.
He joined PA Consulting in 2018 to lead its Americas business. During his time with the firm, he also had global responsibility for healthcare, life sciences, and energy and utilities, served on its board, and became Chief Executive Officer in October 2020.
Earlier in his career, Toombs was Global Head of Infosys Consulting, where he led a practice of more than 3,000 consultants worldwide. He also served as Deputy Chief Executive Officer of Capgemini Consulting and Chief Executive Officer of its North American business, and held senior positions at PricewaterhouseCoopers and IBM.
His areas of experience include strategic development, new venture creation, mergers and acquisitions, post-merger integration and organisational design. Toombs has a B.S. in accounting from the University of Southern California and an M.B.A. from the Kellogg School of Management at Northwestern University. He is based in North Carolina’s Research Triangle region.
#Vogenx’s lead development programme
Vogenx describes itself as a clinical-stage biopharmaceutical company developing treatments for serious metabolic and gastrointestinal diseases. Its lead candidate, mizagliflozin, is an investigational, orally administered small molecule designed to inhibit sodium-dependent glucose transporter 1, or SGLT1.
The company is developing mizagliflozin for post-bariatric hypoglycaemia, gastroparesis and GIP-dependent Cushing’s Syndrome. The source states that the molecule has been administered to more than 500 subjects in 10clinical studies and has produced statistically significant reductions in postprandial glucose absorption, GIP secretion and insulin secretion.
The source also reports improvements in postprandial glucose nadir and Level 2 and Level 3 hypoglycaemia events among patients diagnosed with post-bariatric hypoglycaemia. Mizagliflozin remains investigational, and the announcement does not state that it has received regulatory approval.
#Risks identified by Vogenx
Vogenx said its forward-looking statements are subject to risks and uncertainties. These include the initiation, timing and results of clinical trials, regulatory review, reliance on third parties and the company’s licence from Kissei Pharmaceutical Co., Ltd.
The company also identified its need for additional capital, limited operating history and dependence on a small number of key personnel as risks. It stated that actual results could differ materially from its forward-looking statements.
The announcement does not provide details of Toombs’ remuneration, equity interests or other financial terms associated with the appointment.
#Key Takeaways
- Ken Toombs joined Vogenx’s Board of Directors effective September 21, 2026.
- He will serve as an independent director and Chair of the Audit Committee.
- Toombs previously led PA Consulting and held senior roles at Infosys Consulting, Capgemini Consulting, PricewaterhouseCoopers and IBM.
- Vogenx is developing investigational mizagliflozin for post-bariatric hypoglycaemia, gastroparesis and GIP-dependent Cushing’s Syndrome.
- The company identified clinical, regulatory, financing, licensing and operational risks associated with its forward-looking statements.
Original source: Read original article